Codexis FY2025 EPS Forecast Lowered by Cantor Fitzgerald

Codexis, Inc. (NASDAQ:CDXS - Free Report) - Research analysts at Cantor Fitzgerald decreased their FY2025 earnings estimates for shares of Codexis in a research report issued on Thursday, May 15th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biotechnology company will post earnings of ($0.62) per share for the year, down from their previous forecast of ($0.60). The consensus estimate for Codexis' current full-year earnings is ($0.77) per share.

Separately, Wall Street Zen upgraded shares of Codexis to a "sell" rating in a report on Friday, May 16th.

Codexis Price Performance

Codexis stock traded down $0.06 during mid-day trading on Monday, reaching $2.40. The company had a trading volume of 6,709,925 shares, compared to its average volume of 691,745. Codexis has a fifty-two week low of $1.90 and a fifty-two week high of $6.08. The company has a current ratio of 3.21, a quick ratio of 3.15 and a debt-to-equity ratio of 0.39. The company has a market cap of $198.83 million, a P/E ratio of -2.76 and a beta of 2.56. The business has a fifty day simple moving average of $2.40 and a 200 day simple moving average of $3.69.

Codexis (NASDAQ:CDXS - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.05). The firm had revenue of $7.54 million during the quarter, compared to analyst estimates of $10.38 million. Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%.

Institutional Trading of Codexis

Institutional investors and hedge funds have recently bought and sold shares of the company. Integrity Alliance LLC. purchased a new position in Codexis during the first quarter valued at approximately $30,000. Summit Investment Advisors Inc. boosted its stake in shares of Codexis by 81.4% during the fourth quarter. Summit Investment Advisors Inc. now owns 8,428 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 3,783 shares during the period. US Bancorp DE lifted its stake in Codexis by 11,125.0% in the first quarter. US Bancorp DE now owns 17,960 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 17,800 shares during the period. Wolverine Trading LLC purchased a new stake in Codexis in the fourth quarter worth about $56,000. Finally, Fiduciary Trust Co purchased a new stake in shares of Codexis during the fourth quarter valued at about $65,000. 78.54% of the stock is currently owned by institutional investors.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.